Resource Summary Report

Generated by RRID on Jul 28, 2026

Phospho-TIF1beta (Ser824) Antibody

RRID:AB_2209906
Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 4127, RRID:AB_2209906

Antibody Information

URL: http://antibodyregistry.org/AB_2209906

Proper Citation: Cell Signaling Technology Cat# 4127, RRID:AB_2209906

Target Antigen: Phospho-TIF1beta (Ser824)

Host Organism: rabbit

Clonality: polyclonal

Comments: Applications: W

Antibody Name: Phospho-TIF1beta (Ser824) Antibody

Description: This polyclonal targets Phospho-TIF1beta (Ser824)

Target Organism: h, human

Antibody ID: AB_2209906

Vendor: Cell Signaling Technology

Catalog Number: 4127

Record Creation Time: 20250819T230759+0000

Record Last Update: 20250820T042321+0000

Ratings and Alerts

No rating or validation information has been found for Phospho-TIF1beta (Ser824) Antibody.

No alerts have been found for Phospho-TIF1beta (Ser824) Antibody.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Han Y, et al. (2024) gp78-regulated KAP1 phosphorylation induces radioresistance in breast cancer by facilitating PPP1CC/PPP2CA ubiquitination. iScience, 27(9), 110847.

Nair JR, et al. (2024) Distinct effects of sacituzumab govitecan and berzosertib on DNA damage response in ovarian cancer. iScience, 27(12), 111283.

Huang M, et al. (2023) FACS-based genome-wide CRISPR screens define key regulators of DNA damage signaling pathways. Molecular cell, 83(15), 2810.

Sahgal P, et al. (2023) Replicative stress in gastroesophageal cancer is associated with chromosomal instability and sensitivity to DNA damage response inhibitors. iScience, 26(11), 108169.

Egger T, et al. (2022) A clinically relevant heterozygous ATR mutation sensitizes colorectal cancer cells to replication stress. Scientific reports, 12(1), 5422.

Ka NL, et al. (2021) IFI16 inhibits DNA repair that potentiates type-I interferon-induced antitumor effects in triple negative breast cancer. Cell reports, 37(12), 110138.